NAGIOS: RODERIC FUNCIONANDO

Risk factors for oral mucositis during chemotherapy treatment for solid tumors:a retrospective STROBE-guided study

Repositori DSpace/Manakin

IMPORTANT: Aquest repositori està en una versió antiga des del 3/12/2023. La nova instal.lació está en https://roderic.uv.es/

Risk factors for oral mucositis during chemotherapy treatment for solid tumors:a retrospective STROBE-guided study

dc.contributor.author	Martins, Joyce Ohana de Lima	es
dc.contributor.author	Fontes-Borges, Marcela Maria	es
dc.contributor.author	Malta, Cássia Emanuella Nóbrega	es
dc.contributor.author	Carlos, Anna Clara Aragão Matos	es
dc.contributor.author	Crispim, André Alves	es
dc.contributor.author	de Moura, José Fernando Bastos	es
dc.contributor.author	Silva-Fernandes, Isabelle Joyce de Lima	es
dc.contributor.author	Silva, Paulo-Goberlânio-de Barros	es
dc.date.accessioned	2023-06-16T08:36:49Z
dc.date.available	2023-06-16T08:36:49Z
dc.date.issued	2022	es
dc.identifier.citation	Martins, JO., Borges, MM., Malta, CE., Carlos, AC., Crispim, AA., Moura, JF., Fernandes-Lima, IJ., & Silva, PG. (2022). Risk factors for oral mucositis during chemotherapy treatment for solid tumors: a retrospective STROBE-guided study. En Medicina Oral Patología Oral y Cirugia Bucal (pp. e319-e329). Medicina Oral, S.L. https://doi.org/10.4317/medoral.25253	es
dc.identifier.uri	https://hdl.handle.net/10550/88131
dc.description.abstract	This study retrospectively analyzed the risk factors for transchemotherapy oral mucositis (OM). Before each chemotherapy cycle, patients were routinely evaluated for the presence/severity of OM based on the Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale for adverse effects and graded as follows: However, specific conditions such as mucositis are graded on a five-point scale: 0, absence of mucositis, grade 1 (Asymptomatic or mild), 2 (Presence of pain and moderate ulceration, without interference with food intake), 3 (severe pain with interference with food intake) or 4 (Life-threatening with the need for urgent intervention). Information from 2 years of evaluations was collected and patient medical records were reviewed to obtain data on chemotherapy cycle, sex, age, body mass index, body surface area, primary tumor, chemotherapy protocol, and history of head and neck radiotherapy. The X² test and multinomial logistic regression were used for statistical analysis (SPSS 20.0, p<0.05). Among 19,000 total evaluations of 3,529 patients during 5.32±4.7 chemotherapy cycles (CT) the prevalence of OM was 6.3% (n=1,195). Chemotherapy duration (p<0.001), female sex (p=0.001), adjuvant intention (p=0.008) and the use of carboplatin (p=0.001), cisplatin (p=0.029), docetaxel (p<0.001) and bevacizumab (p=0.026) independently increased the risk of mucositis. In head and neck tumors, 2018 year (p=0.017), chemotherapy duration (p=0.018), BMI>30 (p=0.008), radiotherapy (p=0.037) and use of carboplatin (p=0.046) and cyclophosphamide (p=0.010) increased this prevalence. Cycles of chemotherapy, sex, cytotoxicity drugs, bevacizumab and head and neck radiotherapy increase the risk of OM in solid tumors.	es
dc.subject	sars-cov-2	es
dc.subject	covid-19	es
dc.subject	xrestomia	es
dc.subject	dysgeusia	es
dc.subject	oral manifestation	es
dc.title	Risk factors for oral mucositis during chemotherapy treatment for solid tumors:a retrospective STROBE-guided study	es
dc.type	journal article	es_ES
dc.subject.unesco	UNESCO:CIENCIAS MÉDICAS	es
dc.identifier.doi	10.4317/medoral.25253	es
dc.type.hasVersion	VoR	es_ES
dc.identifier.url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271342/